Stephen M. Stahl, MD, PhD
Adjunct Professor of Psychiatry, University of California San Diego, La Jolla, CA
Honorary Visiting Senior Fellow, University of Cambridge, UK
Director of Psychopharmacology Services and Senior Academic Advisor, California Department of State Hospitals, Sacramento, CA
Editor-in-Chief, CNS Spectrums
Dr. Stephen M. Stahl received his undergraduate and medical degrees from Northwestern University in Chicago, as a member of the Honors Program in Medical Education, and his Ph.D. degree in pharmacology and physiology from the University of Chicago. Dr. Stahl has trained in three specialties: internal medicine at the University of Chicago; neurology at the University of California in San Francisco; and psychiatry at Stanford University. He is board certified in psychiatry.
Dr. Stahl has held faculty positions at Stanford University, the University of California at Los Angeles (UCLA), the Institute of Psychiatry London, the Institute of Neurology London, and, currently, as professor at the University of California at San Diego (UCSD) and as an Honorary Visiting Senior Fellow in the Department of Psychiatry at the University of Cambridge in the UK. He also directs psychopharmacology services and academic programs for the eight facility, 6500 patient California Department of State Hospital System, where he also heads their assessment and treatment efforts to reduce violence. Dr. Stahl was formerly Executive Director of Clinical Neurosciences at the Merck Neuroscience Research Center in the UK for several years. Dr. Stahl’s major interests are dedicated to producing and disseminating educational information about diseases and their treatments in psychiatry and neurology, with a special emphasis on multimedia, the internet and teaching how to teach.
Dr. Stahl currently serves as editor-in-chief of CNS Spectrums. He is also past associate editor of Acta Psychiatrica Scandinavica, former clinical field editor for the International Journal of Neuropsychopharmacology and is currently on numerous editorial boards of other leading journals including the ACNP’s journal Neuropsychopharmacology. He has conducted numerous research projects during his career awarded by the National Institute of Mental Health (NIMH), by the Department of Veteran Affairs (VA) and by the pharmaceutical industry. Author of over 500 articles and chapters, and more than 1600 scientific presentations and abstracts, Dr. Stahl is an internationally reknowned clinician, researcher and teacher in psychiatry with subspecialty expertise in psychopharmacology. Dr. Stahl has written 35 books and edited 12 others, including the best-selling and award winning textbook, Stahl’s Essential Psychopharmacology, now in its fourth edition, the best selling and award winning clinical manual, Essential Psychopharmacology Prescriber’s Guide, now in its fifth edition.
Lectures, courses and preceptorships based upon his textbooks have taken him to dozens of countries on 6 continents to speak to tens of thousands of physicians, mental health professionals and students at all levels. His lectures and scientific presentations have been distributed as more than a million CD-ROMs, internet educational programs, videotapes, audiotapes and programmed home study texts for continuing medical education to hundreds of thousands of professionals in many different languages. His courses and award-winning multimedia teaching materials are used by psychopharmacology teachers and students throughout the world.
Dr. Stahl serves as a fellow of the ACNP (American College of Neuro-psychopharmacology), of the British Association of Psychopharmacology (BAP) and of the CINP, where he was formerly vice president and is a Distinguished Life Fellow of the American Psychiatric Association (APA). He also has served on numerous medical and scientific advisory boards for the pharmaceutical industry, for the biotechnology and medical information industry, and for various nonprofit and public service organizations, including appointment by the State of California and past Chair of the Medi-Cal Oversight Board for Medicines (Drug Utilization Review Board).
His educational research programs are monitoring changes in diagnosing and prescribing behaviors as outcomes from various educational interventions for programs organized by the Neuroscience Education Institute, which he chairs. He also has an active clinical practice specializing in psychopharmacologic treatment of resistant cases.
He has been awarded the International College of Neuropsychopharmacology (CINP) Lundbeck Foundation Award in Education for his contributions to postgraduate education in psychiatry and neurology. His books have won the British Medical Association’s Book of the Year Award and Arbor Scientia has been awarded the business of the year award from the local chamber of commerce. Dr. Stahl is also the winner of the A.E. Bennett Award of the Society of Biological Psychiatry, the APA/San Diego Psychiatric Society Education Award, the UCSD department of psychiatry residency teaching award, and has been cited as both one of “America’s Top Psychiatrists” and one of the “Best Doctors in America.” He was honored with the Distinguished Psychiatrist Award of the APA and gave the Distinguished Psychiatrist Lecture for 2013. Recently, his alma mater Northwestern University honored him by naming their annual award for the best medical student going into psychiatry the Stephen Stahl award. Dr. Stahl was named the 2016 David A Mrazek Memorial Award Winner by the American Psychiatric Association and delivered the Mrazek Lecture at the annual meeting of the APA.
Andrew J. Cutler, MD
Executive Vice President and Chief Medical Officer, Meridien Research, Tampa, FL
Dr. Andrew J. Cutler is EVP and Chief Medical Officer of Meridien Research Group in Tampa, FL. Dr Cutler received his medical degree from the University of Virginia School of Medicine and continued his medical training at the University of Virginia Medical Center where he served as an intern, resident, and chief resident in Psychiatry and Internal Medicine. While at the University of Virginia, he also completed training in dopamine receptor pharmacology and clinical psychopharmacology research. He then served as a Legislative Fellow and Mental Health Advisor to US Senator Paul Wellstone in the 103rd U.S Congress.
He has devoted more than 20 years to clinical research, and he has been principal investigator on more than 400 psychiatric and medical clinical trials. He has also published more than 60 peer-reviewed articles, presented over 100 abstracts at national and international medical meetings, and he has given hundreds of invited CME and promotional talks around the world.
He regularly speaks to professional and community audiences about the evaluation and treatment of mental illnesses such as ADHD, anxiety disorders, bipolar disorder, depression, and schizophrenia. He has received several professional honors and awards, including the Merck Award for outstanding medical scholarship, the University of Virginia Pride Award for outstanding patient care, the William Sorum Award from the American Psychiatric Association, the Effective Legislative Fellow Award from the National Alliance for the Mentally Ill, the Distinguished Clinical Professional Award from the Mental Health Association of Central Florida, and he was chosen by his peers as the best psychiatrist in Orlando 5 years in a row (2003-2007).
Dr. Cutler is a Fellow of the American Psychiatric Association and the Academy of Psychosomatic Medicine, and holds the Certified Physician Investigator (CPI) distinction from the Academy of Physicians in Clinical Research.
|| Ira D. Glick, MD
Professor Emeritus, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA
Adjunct Professor, Department of Psychiatry, New York University School of Medicine, New York, NY
Dr. Ira D. Glick joined the faculty of the Stanford University School of Medicine in July, 1993. He has been Professor of Psychiatry at the University of California, San Francisco (UCSF) from 1968 to 1978 and at the Cornell University Medical College from 1978 – 1993. During his tenure at Cornell, he was also Senior Science Advisor to the Director of the National Institute of Mental Health (from 1988 – 1990). Dr. Glick’s research has focused on 1) the effectiveness of psychiatric hospitalization, 2) the current and future treatment of schizophrenia and mood disorders including combining medication and psychotherapy (both individual as well as family therapy) and 3) the diagnosis and treatment of athletes (Sports Psychiatry).
A 1961 graduate of New York Medical College, Dr. Glick is a 1) Distinguished Fellow of the American Psychiatric Association and founding member of both the American Family Therapy Academy and the International Society of Sports Psychiatry (ISSP) and a member of the Board of Directors of the American Society of Clinical Psychopharmacology (ASCP). Dr. Glick has been elected to membership of the American College of Neuropsychopharmacology (ACNP) and the American College of Psychiatrists. He has authored or co-authored more than 200 scientific articles and book chapters, eight books as well as psychopharmacology curriculums for teachers of 1) psychiatric residents, 2) for medical students and 3) for primary care physicians.
He has received numerous awards for his research and teaching including those from the American Psychiatric Association, American College of Neuropsychopharmacology and the Association of Academic Psychiatry – plus the 2014 K P Soo Award from the Am Psychiatric Association - as well as an “exemplary psychiatrist” from the National Alliance for Mental Illnesses (NAMI). In 2017 he received the Dean Award from the American College of Psychiatrists for his research in Schizophrenia. He was appointed Emeritus Professor at Stanford in 2010. He is now (2017) Visiting Professor at three medical schools—Weill Cornell Medical College, NYU, and UC San Diego—and has recently rejoined the faculty at UC San Francisco.
|| David W. Goodman, MD, FAPA
Director, Adult Attention Deficit Disorder Center of Maryland, Baltimore, MD
Director, Suburban Psychiatric Associates, LLC, Baltimore, MD
Assistant Professor, Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD
Dr. David W. Goodman is Assistant Professor of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine. He is also Director of the Adult Attention Deficit Disorder Center of Maryland in Lutherville and Director of Suburban Psychiatric Associates, LLC.
A 1983 graduate of Albany Medical College of Union University, Dr. Goodman completed a medical/psychiatric internship at Baltimore City Hospital and his psychiatric residency at The Johns Hopkins Hospital in 1986.
Dr. Goodman has continued a full time clinical practice focusing on the diagnosis and treatment of mood disorders, adult Attention Deficit/Hyperactivity Disorder, Anxiety Disorders. For almost 30 years, he has been teaching psychiatric residents at The Johns Hopkins Hospital. Dr. Goodman has presented over 600 lectures to primary care physicians, psychiatrists, medical specialists and the general public. His psychiatric commentary has been featured on national (ABC World News, CNN Anderson Cooper 360, ESPN Sports Center) and regional television around the country, PBS and national affiliate stations, national magazines (U.S. News and World Report, Wall Street Journal, New York Times, USA Weekend Magazine, Boston Globe, BusinessWeek) and radio interviews around the country. Dr. Goodman has been an ADHD consultant to Major League Baseball and is now a consultant to the National Football League.
Dr. Goodman has been a Principal Investigator for multi-site Phase II and III drug trials for the treatment of adult Attention Deficit/Hyperactivity Disorder and Major Depression. Dr. Goodman is the lead author on the largest adult ADHD trial published and the lead author on the largest survey assessment of physician clinical practice for adults with ADHD. He has published articles in peer-reviewed journals, authored four book chapters and The Black Book of ADHD. He serves as a prepublication peer reviewer for several national and international psychiatric journals. He continues to treat patients in a full time clinical practice.
|| Rona J. Hu, MD
Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences; Medical Director, Acute Psychiatric Inpatient Unit; Stanford University School of Medicine, Stanford, CA
Dr. Rona J. Hu received her medical degree in 1990 from the University of California, San Francisco School of Medicine, and completed her residency at the University of California, San Francisco Medical Center in 1994. She received her board certification in psychiatry in 1995 from the American Board of Psychiatry and Neurology.
Dr. Hu completed two fellowships while at the National Institutes of Health (NIH) from 1994-1998. She completed the PRAT (Pharmacology Research Associate Training) program from 1994-1996, and a schizophrenia research fellowship from 1996-1998.
Dr. Hu received the 2016 APA Nancy Roeske award for Excellence in Medical Student Education, the 2017 Faculty Award from Stanford University's Asian American Activities Center, and the 2017 Community Engagement Award from Stanford Department of Psychiatry.
|| Roger S. McIntyre, MD, FRCPC
Professor, Departments of Psychiatry and Pharmacology; Head, Mood Disorders Psychopharmacology Unit, University Health Network; University of Toronto, Toronto, ON, Canada
Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada.
Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade.
Dr. McIntyre is involved in multiple research endeavours which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.
Dr. McIntyre is extensively involved in medical education. He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto, Department of Psychiatry and has been a recipient of the joint Canadian Psychiatric Association (CPA) / Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada.
Dr. McIntyre is a contributor to the “Florida Medicaid Drug Therapy Management Program for Behavioral Health: Guidelines for the treatment of adults with Major Depressive Disorder and Bipolar Disorder”. Dr. McIntyre is also the co-chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force on the Treatment of Comorbidity in Adults with Major Depressive Disorder or Bipolar Disorder and as well a contributor to the “CANMAT Guidelines for the Treatment of Depressive Disorders and Bipolar Disorders”. Dr. McIntyre has published hundreds of peer-reviewed articles and has edited and/or co-edited several textbooks on mood disorders.
Dr. McIntyre completed his medical degree at Dalhousie University. He received his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto.
|| Jonathan M. Meyer, MD
Assistant Clinical Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA
Psychopharmacology Consultant, California Department of State Hospitals, Sacramento, CA
Dr. Jonathan M. Meyer is a graduate of Stanford University and Harvard Medical School, and finished his adult psychiatry residency at Los Angeles County-USC Medical Center. At LA County-USC he subsequently completed fellowships in Consultation/Liaison Psychiatry and Psychopharmacology Research.
In addition to teaching duties at UC San Diego, Dr. Meyer has performed extensive research on the metabolic effects of antipsychotics, and the impact of antipsychotic medications on glucose-insulin homeostasis. Dr. Meyer has published numerous articles and book chapters on various aspects of antipsychotic psychopharmacology including the pharmacokinetics of oral and depot antipsychotics, metabolic effects of atypical antipsychotics, as well as on the health care outcomes in patients with severe mental illness. Dr. Meyer is a national speaker on the subject of side effects and metabolic issues surrounding antipsychotic therapy, is chief editor of Medical Illness and Schizophrenia, now in its 2nd edition, and is the sole author of the chapter on the “Pharmacotherapy of Psychosis and Mania” in the last two editions of Goodman & Gilman's The Pharmacological Basis of Therapeutics.
|| Mary D. Moller, DNP, ARNP, PMHCNS-BC, CPRP, FAAN
Associate Professor, Pacific Lutheran University School of Nursing, Tacoma, WA
Director of Psychiatric Services, Northwest Center for Integrated Health, Tacoma, WA
Dr. Mary D. Moller is an internationally known psychiatric mental health nurse clinician, researcher, educator, and presenter. She is an advanced registered nurse practitioner who is dually certified as a clinical specialist in adult psychiatric-mental health nursing and a psychiatric rehabilitation practitioner. She is an Associate Professor at Pacific Lutheran University in Tacoma, WA where she is coordinator of the psychiatric nurse practitioner Doctor of Nursing Practice program. Her teaching foci include psychopharmacology, psychopathology, group therapy, 1:1 psychotherapy, mental health assessment and advanced practice nursing including legislative activity related to independent practice.
She is also the Director of Psychiatric Services for Northwest Center for Integrated Health in Tacoma, WA where she is in practice as a psychiatric ARNP treating patients in a triple integration agency: substance abuse, mental illness, and primary care. She is implementing psychiatric wellness protocols for relapse prevention across the three disciplines.
From January 2009-August, 2014 she was Director of the Psychiatric-Mental Health Nurse Practitioner specialty at the Yale University School of Nursing. While in Connecticut, Mary was in practice as an APRN at Yale Behavioral Health of Hamden, an outpatient mental health center that served patients with co-occurring disorders.
From 1993-2008 she was owner and Clinical Director of The Suncrest Wellness Center, located in Spokane, WA, the first independent nurse managed owned and operated rural outpatient psychiatric clinic in the United States. Suncrest was featured with Patty Duke on Good Morning America. In addition to her administrative duties and ongoing program research and QI activities, she managed a full caseload of over 300 patients where she was responsible for primary mental health care including prescribing and monitoring psychotropic medications, conducting group therapy, and group psychoeducation on recovery from trauma, relapse prevention, and recovery from psychosis.
She has published over 100 peer-reviewed articles, book chapters, policy statements, conference proceedings, newsletter articles, training manuals, and professional videotapes. She is the producer and director of the award winning Understanding and Communicating With video series that has four videos. Mary has authored two books including a Mosby pharmacology review book and a new undergraduate psychiatric nursing textbook published by Pearson in January 2015 titled Psychiatric-Mental Health Nursing: From Suffering to Hope.
She is currently the first nurse to serve as an Associate Editor of Clinical Psychiatry. She has served on the editorial boards of The Journal of the American Psychiatric Nurses Association, Journal of Philosophy and Ethics in Healthcare and Medicine, Psychiatric Rehabilitation Journal; a journal of the National Alliance For The Mentally Ill And The Center For Psychiatric Rehabilitation at Boston University, The Journal of the California Alliance for the Mentally Ill, and Directions In Psychiatric Nursing.
She is currently a reviewer for Archives in Psychiatric Nursing, Journal of the American Psychiatric Nurses Association, Qualitative Health Research, Journal of Midwifery and Womens Health, and Perspectives in Psychiatric Care.
She has made over 1000 professional and research presentations in all 50 states, Alberta, Australia, British Columbia, China, Cuba, England, Denmark, Hong Kong, Israel, Ontario, Singapore, and Quebec. She has received numerous awards including induction as a Fellow in the American Academy of Nursing, President of the American Psychiatric Nurses Association, Distinguished Service Award from the American Psychiatric Nurses Association, Distinguished Alumnus from the University of Nebraska College of Nursing Medical Center, Award for Clinical Excellence from the American Psychiatric Nurses Association, and the AAPPN Award for Clinical Excellence. She was Co-PI and Curriculum co-coordinator for a 5-year SAMHSA grant through the APNA entitled Recovery to Practice. She is currently President-Elect of the Washington State Association of Advanced Practice Psychiatric Nurses. She is also the current ANA representative to the JCAHO Psychiatric Professional and Technical Advisory Committee.
Her research interests include psychological adjustment to and symptom management in recovery from schizophrenia, a wellness approach to symptom management of recovery from trauma and abuse, and most recently identification of motivational strategies for nurse recruitment and retention based on self-determination theory. From 2009-2014 she served as part of the grant writing team and curriculum co-chair for the SAMHSA Recovery to Practice project with the American Psychiatric Nurses Association.
She is the co-developer of the Murphy-Moller Wellness Model that serves as the centerpiece of the Three R’s Psychiatric Rehabilitation Recovery Program. Rehospitalization rates for participants with serious mental illness enrolled in the program are reduced by 93.5%. These results have been replicated nationally and internationally.
|| Adelaide Robb, MD
Chief, Psychology and Behavioral Health, Children’s National Medical Center, Washington, DC
Dr. Adelaide Robb is a psychopharmacologist with ongoing research studies in mood disorders, schizophrenia, and post traumatic stress disorder, and Chief of the Division of Psychology and Behavioral Health, which aims to combine psychological and psychiatric services to treat the medically ill child.
Dr. Robb, who trained at Johns Hopkins University and the National Institutes of Health, has been on the medical staff in the Division of Psychiatry and Behavioral Medicine since 1996, rising to the rank of Professor (with tenure). She is an internationally known clinical researcher and has participated in and led multiple therapeutic trials for children with a variety of behavioral and psychiatric conditions.
|| William M. Sauvé, MD
Medical Director, Greenbrook TMS NeuroHealth Centers, Glen Allen and Charlottesville, VA
Dr. William M. Sauvé received his medical degree from the Uniformed Services University of the Health Sciences in Bethesda, Maryland, and completed his residency in adult psychiatry at the National Capitol Consortium in Washington, DC, prior to deploying to the Al Anbar Province, Iraq, as the Regimental Psychiatrist for the 7th Marines.
After eleven years of active duty service, Dr. Sauvé left the United States Navy to become the Clinical Director of the Military Program at Poplar Springs Hospital in Petersburg, VA, an inpatient structured program for the treatment of Posttraumatic Stress Disorder and Chemical Dependency that caters exclusively to the military population. In 2014, he left Poplar Springs Hospital to focus on Transcranial Magnetic Stimulation and now serves as the Medical Director for TMS NeuroHealth Centers in Richmond (Glen Allen) and Charlottesville, VA. Dr. Sauvé also consults for pharmaceutical companies and associated industries as well.
He is a member of the American Psychiatric Association, and certified by the American Board of Psychiatry and Neurology. Dr. Sauvé also recently co-authored “Psychopharmacological Treatment,” with Dr. Stahl, a chapter in Treating PTSD in Military Personnel, edited by Bret Moore and Walter Penk.
|| Thomas L. Schwartz, MD
Professor and Vice Chair, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY
Dr. Thomas L. Schwartz, MD, is currently professor and interim chair of psychiatry at SUNY Upstate Medical University. Active on many teaching, administrative and curriculum committees at SUNY, he also provides direct resident supervision, lectures in several courses, and directs and organizes continuing medical education events for the psychiatry department.
Dr. Schwartz received his medical degree from and completed his residency in adult psychiatry at the State University of New York (SUNY) Upstate Medical University in Syracuse, New York.
Dr. Schwartz’s abilities as a medical educator have been recognized with the Marc H. Hollander, MD, Psychiatry Award, Teacher of the Year, and Mentor of the Year awards from SUNY Upstate Medical University; Nancy Roeske, MD, Irma Bland, Certificates of Recognition for Excellence in Medical Student and Resident Education from the American Psychiatric Association, the SUNY Upstate President’s and the SUNY Chancellor’s Award for Teaching.
Dr. Schwartz is the author of Practical Psychopharmacology: Basic to Advanced Principles, Stahl’s Essential Psychopharmacology Case Studies Volume 2, Integrating Psychotherapy and Pharmacotherapy, Antipsychotic Drugs: Pharmacology, Side Effects and Abuse Prevention, Second and Third Generation Antipsychotics. He is the editor of Depression: Treatment Strategies and Management, 1st and 2nd Eds. and is the Deputy Editor for the journal CNS Spectrums.
|| Timothy E. Wilens, MD
Chief, Division of Child and Adolescent Psychiatry, Co-Director, Center for Addiction Medicine
MGH Trustees Endowed Chair in Addiction Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Dr. Timothy E. Wilens is Associate Professor of Psychiatry at Harvard Medical School in Boston, Massachusetts. In addition, he is Director of Substance Abuse Services in the Clinical and Research Program in Pediatric Psychopharmacology at Massachusetts General Hospital. Dr. Wilens earned his BS in literature, science, and arts at the University of Michigan Honors College and his MD at the University of Michigan Medical School in Ann Arbor. His residency in child, adolescent, adult, and addiction psychiatry was completed at Massachusetts General Hospital under the auspices of Harvard Medical School in Boston.
Dr. Wilens' research interests include the relationship among attention deficit/hyperactivity disorder (ADHD), bipolar disorder, and substance abuse, and the pharmacotherapy of ADHD and juvenile bipolar disorder across the lifespan. His peer-reviewed articles concerning these and related topics number more than 200, and are published in prestigious journals such as the American Journal of Psychiatry, Archives of General Psychiatry, and Pediatrics. Dr. Wilens has also published more than 60 book chapters, and 300 abstracts and presentations for national and international scientific meetings.
Dr. Wilens is a Distinguished Fellow of the American Psychiatric Association and the American Academy of Child and Adolescent Psychiatry, serves as a scientific reviewer for 22 journals, and is active in a number of other local and national professional societies. Dr. Wilens is named consistently among "The Best of Boston" in Child/Adult Psychiatry and "The Best Doctors in America."